The results of clinical samples show that TOPK and p-TOPK are expressed at elevated levels in GC, patients with high expression of TOPK and p-TOPK have shorter survival, and TOPK as a downstream molecule of FYN is also a cancer-promoting factor in GC. This evidence concerns the gene FYN and cancer.